UroGen Pharma Ltd. Ordinary Shares (URGN) is a publicly traded Healthcare sector company. As of October 19, 2026, URGN trades at $33.82 with a market cap of $1.69B and a P/E ratio of -18.98. URGN moved -1.94% today. Year to date, URGN is +47.57%; over the trailing twelve months it is +104.14%. Its 52-week range spans $3.42 to $50.81. Analyst consensus is strong buy with an average price target of $60.20. Rallies surfaces URGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
FDA accepts UroGen's UGN-103 application for bladder cancer treatment: The FDA accepted UroGen Pharma’s UGN-103 application to treat adults with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer and set a June 14, 2027, target action date.
| Metric | Value |
|---|---|
| Price | $33.82 |
| Market Cap | $1.69B |
| P/E Ratio | -18.98 |
| EPS | $-1.97 |
| Dividend Yield | 0.00% |
| 52-Week High | $50.81 |
| 52-Week Low | $3.42 |
| Volume | 96.91K |
| Avg Volume | 0 |
| Revenue (TTM) | $188.73M |
| Net Income | $-97.64M |
| Gross Margin | 90.84% |
5 analysts cover URGN: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $60.20.